Reimagining Mental Health Q3 2025 Earnings Presentation • November 6, 2025 Forward-Looking Statements DISCLAIMERS Cautionary Note Regarding Forward-Looking Statements This presentation and related oral statements, including during any question and answer portion of the presentation, contain forward-looking statements about LifeStance Health Group, Inc. and its subsidiaries ("LifeStance") and the industry in which LifeStance operates, including statements regarding: full-year and fourth quarter guidance and ...

Third Quarter 2025 Performance - Organic growth contracted by 1.6% due to a 0.5% volume decline, but trends improved sequentially throughout the quarter[8] - Category sales growth accelerated to 2%+ value growth[8] - Adjusted gross margin decreased by 420 bps year-over-year due to higher COGS inflation[8] - Adjusted EBITDA declined 14% year-over-year, and Adjusted EPS fell 11%[8] - Total revenue was €752 million, a 2.2% decrease from €770 million in 3Q 2024[23] - Adjusted gross profit decreased by 15% from €248 million to €212 million[23] - Adjusted EBITDA was €143 million, a 14% decrease from €166 million[23] - Adjusted EPS was €0.49, an 11% decrease from €0.55[23] Cash Flow and Capital Allocation - The company returned cash to shareholders through share repurchases (€151 million YTD) and dividend payments (€70 million YTD), collectively up 100% year-over-year[8] - Adjusted free cash flow was €66 million for the nine months ended September 30, 2025, compared to €105 million for the same period in 2024[24] Outlook - Management expects to deliver full-year 2025 results near the low-end of its organic revenue, Adjusted EBITDA, and Adjusted EPS ranges[8] - The company is guiding to the low end of its existing 2025 ranges, with organic revenue between 0% to -2%, and Adjusted EBITDA between -3% to -7% year-over-year[27]

Third Quarter 2025 EARNINGS PRESENTATION November 6 | 2025 FORWARD LOOKING STATEMENTS & OTHER INFORMATION This document contains forward-looking statements. within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Company's representatives may also make forward-looking statements orally or in writing from time to time. Statements in this document that are not historical fac ...

Forward-Looking Statements Some of the statements contained in this presentation may constitute forward-looking statements within the meaning of the federal securities laws. Forward-looking statements relate to expectations, projections, plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology such as ''may,'' ''will,'' ''should,'' ''expects ...

Financial Performance & Strategy - Total revenue for Q3 2025 was $70 million, a decrease of 18% compared to $85 million in Q3 2024[25] - The company achieved $1.1 billion in non-dilutive funding over the past 8 quarters[14] - Novavax is aiming for Non-GAAP profitability as early as 2028, driven by diversified revenue streams[15] - Combined R&D and SG&A expenses for Q3 2025 decreased by 18% compared to Q3 2024[22] - The company anticipates combined R&D and SG&A expenses less partner reimbursement of approximately $350 million for FY 2026 and $250 million for FY 2027[35] Sanofi Partnership - Sanofi revenue in Q3 2025 was $48 million, including $4 million in COVID-19 royalties[23, 28] - Novavax expects $60 million in cash from Sanofi by Q1 2026 related to the COVID-19 commercial role transition[23] - The Sanofi partnership is projected to result in $230 million in operating cost savings over 11 years[23] 2025 Financial Outlook - Adjusted Total Revenue for full year 2025 is projected to be between $1040 million and $1060 million[39] - Nuvaxovid product sales are expected to be $610 million for full year 2025, including $603 million from the termination of the Canada and New Zealand Advance Purchase Agreements[39] Pipeline Development - The company is advancing an early-stage pipeline focused on diseases with high unmet medical needs, including Varicella Zoster Virus (Shingles), C difficile, RSV combinations, and Pandemic Flu[14, 19]

NON-GAAP FINANCIAL MEASURES We define Adjusted EBITDA, which is a non-GAAP financial measure, as net income (loss) excluding income taxes, non-operating income or expenses, gain (loss) on extinguishment of debt and write-off of deferred financing costs, gain (loss) on interest rate swap contracts, gain (loss) on derivative contracts, gain (loss) on investments and sale of affiliate interests, interest expense, net, depreciation and amortization, share-based compensation, restructuring, impairments and other ...

Financial Performance - Revenue increased by 2% year-over-year to $272.6 million, but decreased by 1% on a constant currency basis[31] - Gross profit increased to $170.1 million, with a gross margin of 62.4%, up 110 basis points year-over-year[47, 48] - The company reported a net loss attributable to shareholders of $15.2 million, compared to a net income of $5.4 million in the same quarter last year[47] - Adjusted EBIT was a loss of $14.2 million, compared to a profit of $2.5 million in the prior year[47] Channel Performance - DTC revenue increased by 22% year-over-year (21% in constant currency) to $126.6 million[32, 39] - DTC comparable sales growth was 10% year-over-year, marking ten consecutive months of positive comps[27, 32, 39] - Wholesale revenue decreased by 1% year-over-year (5% in constant currency) to $135.9 million[34, 39] - Other revenue decreased significantly by 62% year-over-year (63% in constant currency) to $10.1 million, due to fewer events and employee sales[32, 34, 37] Geographic Performance - Asia Pacific revenue increased by 20% year-over-year (20% in constant currency) to $79.3 million[41, 46] - North America revenue decreased by 7% year-over-year (8% in constant currency) to $112.1 million[41, 46] - EMEA revenue increased by 1% year-over-year (-7% in constant currency) to $81.2 million[41, 43] Balance Sheet - Inventory levels decreased by 3% year-over-year[50, 51] - Net debt decreased year-over-year to $707.1 million[50, 51]

November 6, 2025 ASPEN AEROGELS Q3 2025 FINANCIAL RESULTS CALL The presentation contains information regarding certain financial targets and outlook with respect to the Company. Such financial targets and outlook constitute forward looking information and is for illustrative purposes only and should not be relied upon as necessarily being indicative of future results. The assumptions and estimates underlying such financial targets are inherently uncertain and are subject to a wide variety of significant bus ...

MKS Inc. November 6, 2025 Safe Harbor for Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 regarding the future financial performance, business prospects and growth of MKS Inc. ("MKS," the "Company," "our," or "we"). These statements are only predictions based on current assumptions and expectations. Any ...

Financial Performance - Consolidated revenue increased by 8.1% to $406 million[12] - Adjusted EBITDA increased by 9.5% to $133 million[12] - Adjusted Funds From Operations (AFFO) increased significantly by 62.5% to $30 million[12] Segment Results - America segment revenue increased by 5.9% to $310 million[13], with digital revenue up by 6.9% to $113 million[15] - Airports segment revenue increased substantially by 16.1% to $96 million[16], driven by strong advertising demand and a 37.4% increase in digital revenue to $58 million[18] Capital Expenditures - Total capital expenditures decreased by 25.9% to $13 million[20], driven by lower digital spend in America[22] - Capital expenditures for the Airports segment increased by 20.4% to $4 million[20], reflecting continued digital expansion[22] Strategic Initiatives - An agreement was entered into to sell the business in Spain to Atresmedia for approximately $135 million[9, 49] - The sale of the business in Brazil was closed on October 1st for $15 million[9, 48] Guidance - The company expects a strong fourth quarter and has tightened full-year revenue ranges and raised AFFO guidance[9] - Full-year 2025 consolidated revenue is projected to be between $1.584 billion and $1.599 billion[27], representing a 5% to 6% increase from the prior year[27]